ArticleFrontiers in public health2025
Neonatal encephalopathy due to birth asphyxia and trauma: global trends and disparities.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neonatal encephalopathy due to birth asphyxia and trauma (NE-BAT) is a leading cause of neonatal mortality and long-term neurodevelopmental disabilities, particularly in low- and middle-income regions. Methods: Using the Global Burden of Disease (GBD) 2021 dataset, we analyzed global incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of NE-BAT from 1990 to 2021. We examined age-standardized rates, estimated annual percentage changes (EAPC), socio-demographic index (SDI) quintiles, gender differences, and used autoregressive integrated moving average (ARIMA) models for 2031 projections. Results: From 1990 to 2021, global age-standardized incidence rate declined from 20.22 to 17.16 per 100,000 (EAPC: -0.56), while prevalence increased from 129.73 to 242.03 per 100,000 (EAPC: 2.16). Males had higher incidence (19.93 vs. 14.18 per 100,000) and prevalence (291.46 vs. 191.38 per 100,000) than females. Mortality declined from 13.81 to 9.75 per 100,000 (EAPC: -1.24), and DALYs decreased from 1270.67 to 932.14 per 100,000 (EAPC: -1.12). Low SDI locations had NE-BAT-specific mortality rates 27 times higher than high SDI locations (17.77 vs. 0.66 per 100,000 in 2021). Projections to 2031 suggest continued declines in incidence and DALYs but rising prevalence and mortality rates. Conclusion: While global burden of NE-BAT has improved through reduced incidence and DALYs, persistent gender and regional disparities, along with rising prevalence rates, pose ongoing challenges. Targeted interventions addressing these disparities, particularly in low SDI locations, are essential to improve neonatal outcomes and reduce health inequalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.